Company intelligence / Profile preview

New Taihe Biopharmaceutical

Shenzhen, Guangdong, China

Ownership: Private
Development stage: Other

Overview

New Taihe Biopharmaceutical is focused on developing targeted prodrugs and Peptide-Drug Conjugates (PDCs) using its proprietary Legumain-targeted platform. Its lead candidate, NT-001, is a targeted doxorubicin prodrug that selectively releases its payload in the tumor microenvironment, significantly reducing cardiotoxicity and systemic side effects in patients with advanced solid tumors.

Therapeutic areas: OncologyEndocrinology
Modalities: Small moleculePeptide-drug conjugateTargeted prodrugRecombinant protein
Industry: Biotech

Partnerships

Sichuan University (Clinical monitoring/design)

Beyond the preview

Go deeper on New Taihe Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New Taihe Biopharmaceutical.

Explore the full profile